Researchers from the University of Michigan and U.S. Centers for Disease Control and Prevention have analyzed the cost-effectiveness of influenza vaccination, finding that this varies by age and risk status, and was less than $95,000 per quality-adjusted life year (QALY) for all subgroups, except for non-high-risk working-age adults. A state transition simulation model was constructed to estimate the health and economic outcomes of influenza vaccination compared to no vaccination for hypothetical US cohorts stratified by age and risk status. Further highlights from the study published in Vaccine can be found below.
Cost-effectiveness of influenza vaccination varies by age and risk status.
Influenza vaccination is economically attractive for most age and risk groups.
Vaccination of healthy adults 18–49 years may exceed common cost-effectiveness thresholds.
Vaccination of higher risk groups are below common thresholds at low vaccine effectiveness.
Lower cost settings improve cost-effectiveness of influenza vaccination
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.